{"name":"Alnylam Pharmaceuticals, Inc.","slug":"alnylam","ticker":"ALNY","exchange":"NASDAQ","domain":"alnylam.com","description":"Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its \"100 Most Innovative Growth Companies\" list.","hq":"Cambridge, MA","founded":0,"employees":"2500","ceo":"Yvonne Greenstreet","sector":"Biotech","stockPrice":327.49,"stockChange":7.97,"stockChangePercent":2.49,"marketCap":"$43.4B","metrics":{"revenue":3100000000,"revenueGrowth":84.9,"grossMargin":81.6,"rdSpend":1319775000,"netIncome":313747000,"cash":2908484096,"dividendYield":0,"peRatio":140.6,"fiscalYear":"FY2022"},"revenueBreakdown":[{"name":"Amvuttra","genericName":"VUTRISIRAN","slug":"vutrisiran","revenue":1100000000,"yoyGrowth":0,"percentOfTotal":35.5},{"name":"Onpattro","genericName":"PATISIRAN","slug":"patisiran","revenue":700000000,"yoyGrowth":0,"percentOfTotal":22.6},{"name":"Onpattro","genericName":"PATISIRAN SODIUM","slug":"patisiran-sodium","revenue":700000000,"yoyGrowth":0,"percentOfTotal":22.6},{"name":"Givlaari","genericName":"GIVOSIRAN","slug":"givosiran","revenue":400000000,"yoyGrowth":0,"percentOfTotal":12.9},{"name":"Oxlumo","genericName":"LUMASIRAN","slug":"lumasiran","revenue":200000000,"yoyGrowth":0,"percentOfTotal":6.5}],"timeline":[{"date":"2018-01-01","label":"Onpattro first approved","drug":"Onpattro","drugSlug":"patisiran","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Onpattro first approved","drug":"Onpattro","drugSlug":"patisiran-sodium","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Givlaari first approved","drug":"Givlaari","drugSlug":"givosiran","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Oxlumo first approved","drug":"Oxlumo","drugSlug":"lumasiran","type":"approval","sentiment":"positive"},{"date":"2022-01-01","label":"Amvuttra first approved","drug":"Amvuttra","drugSlug":"vutrisiran","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Onpattro patent cliff ($1.4B at risk)","drug":"Onpattro","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Givlaari patent cliff ($1.1B at risk)","drug":"Givlaari","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Oxlumo patent cliff ($500M at risk)","drug":"Oxlumo","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":2500000000,"percentOfTotal":80.6,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Amvuttra","genericName":"VUTRISIRAN","slug":"vutrisiran","indication":"Transthyretin familial amyloid polyneuropathy","status":"marketed","revenue":1100000000},{"name":"Onpattro","genericName":"PATISIRAN","slug":"patisiran","indication":"Polyneuropathy in amyloidosis","status":"marketed","revenue":700000000},{"name":"Onpattro","genericName":"PATISIRAN SODIUM","slug":"patisiran-sodium","indication":"Polyneuropathy in amyloidosis","status":"marketed","revenue":700000000}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":400000000,"percentOfTotal":12.9,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Givlaari","genericName":"GIVOSIRAN","slug":"givosiran","indication":"Hepatic porphyria","status":"marketed","revenue":400000000}]},{"name":"Other","slug":"other","revenue":200000000,"percentOfTotal":6.5,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Oxlumo","genericName":"LUMASIRAN","slug":"lumasiran","indication":"Primary hyperoxaluria, type I","status":"marketed","revenue":200000000}]}],"pipeline":[{"name":"Amvuttra","genericName":"VUTRISIRAN","slug":"vutrisiran","phase":"marketed","mechanism":"Amvuttra works by silencing the production of abnormal TTR protein through RNA interference.","indications":["Transthyretin familial amyloid polyneuropathy"],"catalyst":""},{"name":"Onpattro","genericName":"PATISIRAN","slug":"patisiran","phase":"marketed","mechanism":"Onpattro works by silencing the production of abnormal TTR protein using small interfering RNA.","indications":["Polyneuropathy in amyloidosis","Transthyretin familial amyloid polyneuropathy"],"catalyst":""},{"name":"Onpattro","genericName":"PATISIRAN SODIUM","slug":"patisiran-sodium","phase":"marketed","mechanism":"Onpattro works by silencing the production of abnormal TTR protein through RNA interference.","indications":["Polyneuropathy in amyloidosis","Transthyretin familial amyloid polyneuropathy"],"catalyst":""},{"name":"Givlaari","genericName":"GIVOSIRAN","slug":"givosiran","phase":"marketed","mechanism":"Givlaari works by binding to and silencing the messenger RNA (mRNA) that produces the enzyme aminolevulinate synthase 1 (ALAS1), which is overproduced in patients with hepatic porphyria.","indications":["Hepatic porphyria"],"catalyst":""},{"name":"Oxlumo","genericName":"LUMASIRAN","slug":"lumasiran","phase":"marketed","mechanism":"Oxlumo works by binding to and silencing the mRNA that produces the enzyme Hydroxyacid oxidase 1, which is overactive in patients with Primary hyperoxaluria, type I.","indications":["Primary hyperoxaluria, type I"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Alnylam reported fourth quarter and full year 2023 financial results, with revenue of $1.4 billion and a net loss of $1.1 billion.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Alnylam Pharmaceuticals Announces Collaboration with Sanofi to Develop RNAi Therapeutics for Rare Genetic Diseases","summary":"Alnylam entered into a collaboration with Sanofi to develop RNAi therapeutics for rare genetic diseases.","drugName":"","sentiment":"positive"},{"date":"2023-06-30","type":"regulatory","headline":"Alnylam Pharmaceuticals Receives FDA Approval for Leqvio (inotersen) for the Treatment of Polyneuropathy in Patients with Hereditary Transthyretin-Mediated Amyloidosis","summary":"Alnylam received FDA approval for Leqvio (inotersen) for the treatment of polyneuropathy in patients with hereditary transthyretin-mediated amyloidosis.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxNd0tJX1JoVVZVdDltcDdqSlp0aExUV004U2FWeXNjeHcwMXVhbG9Uc0ZYOTRkVnpLcmdOWGNtcXNibWdrZFl2ZWZxeEZURDY0ZlJFZmtsdnZoN09oZjhGRUlBSUhOVFJrSlktMnRtbnNfYU5yNFhKVXVuRmVKNWt4cUIwNEpkM1FOZmZXQ1JlWV9WQnFyeGI5dW1jS3p3YkVRYUJGVThKUERRTU1FLUNuRi1pcERublNKemZHdEF3UjNXbG9XWXlZLWY1aGR3RnE3TlBLS29KNzd5NERHZnF3UFIxRG9CZy0ySmprVmNmdnhGLXJFOGdwakp6c0hucHR3ZFFWb1JyQ1BlODdJMHV5eE5qSU8tYng4bVp5VEdSX0Y3Z09IanJlZTQxcTlwZw?oc=5","date":"2026-03-26","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxQNVI1VEtMWEZaS2ZDM09MVTY3eHBEcHVpMFZ4RDczTkxoWHI0SFprSFFXanNBZFNfX2U3LWZ2SG1BeG1wVV9PYUcxb2xtUjZyelpYZ3p1VGx2MHRtaEJyRmtyX3dwbGFCU2wycVFDalZ5TDc4bDlJNFdpY2VjZ1hOQmgzQ05DVHVES2tJN2plU2YxUklSOEpaaXluMmRFQl91OGx0TXViazdMaTQtN2wzRWRFMzhLZi00Q3FZLTVtRkVWRDhaVFhoX2hxcEtYNmlUTU5WemdqNDlMWUtuQnBUdDM0al9sRm5jNjZ6YzIwNXRLSndnQmoyUnVtWGFDMGd3U2dr?oc=5","date":"2026-02-12","type":"pipeline","source":"FinancialContent","summary":"Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance - FinancialContent","headline":"Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxQWnp4SmxSUWpDenVMVmVIcVQ1S05DSk1qMVZBRWwxR05CalRmMXdqYVNTZGZDLWNKZS1zYi1nazFILV9LVEdHWV9MWWJuUWFsSm1MWElQSzdKVVFZRElFWDRWY0p2amtZNm9TbkZJTTN4YTlQUGk2b0pUQXZqTk9XRXNfY0J4MUpGYjIxbVdtRFRNajczbnZNaE9pSVNvWFM2OF9ycGliRy1aMzhpZUxxb3JaS2Z5Vmg4R2JUeU80SVFQZVVlSGdnczFaT1dZcGdfbXdQUTNDVTNQVjh4MHpnX3lsOHQ4aWhONGJtRi1zR3B1LWMzZE9UdzNFdEpYcWg0TXlQbjFJU3FTUQ?oc=5","date":"2026-02-12","type":"earnings","source":"Business Wire","summary":"Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress - Business Wire","headline":"Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progres","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNNVplS1YxOHdYbmdseXlPQjRRUGZfQnVtdDlUdHg2MkF5d25yeVBPOXdWejZFMXNpZm9KNTBjUHVTa1JmaUliU2ZCQkw5RkJGa2FCOXMydHNacmEyMGZ1OXZUbHFuMWl1ajN5SlFxakhQTUpHandUdDRlVkNwZmNRV3pnSEZ6NFI3LThnY013QXVNY3ZLX0hyOUpOX0JLTHhxRldGREZFZi1nQkU?oc=5","date":"2026-02-08","type":"pipeline","source":"TIKR.com","summary":"Down 34% From All-Time Highs, Can Alnylam Pharmaceuticals Stock Finally Recover In 2026? - TIKR.com","headline":"Down 34% From All-Time Highs, Can Alnylam Pharmaceuticals Stock Finally Recover In 2026?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPUlZ1TUhMZElhVnB3WGgwOTd4Q0ZWTGI2XzlZRDM1ellWSHFiaHczd3dOekJOV3EyYVJxRmdEdVNTVmUyZlp3aFhvYktHeEJqbmdEazhiVHRxUFZrRlpwOVNtZmZUUXRQR2dUVmhNckNpdktuclBPbXFmcHRZT2UwdHpad2c2dGVDZ25lN1o4WGtsY3RHWXFNYms3Q0ZPNUdfU3pYMkg1NEFtWjlmMEg5aUJRQmhSRlhqalJIVl9mT1M3QWtxSVE?oc=5","date":"2026-01-12","type":"pipeline","source":"Benzinga","summary":"What's Going On With Alnylam Pharma Stock Monday? - Alnylam Pharmaceuticals (NASDAQ:ALNY) - Benzinga","headline":"What's Going On With Alnylam Pharma Stock Monday? - Alnylam Pharmaceuticals (NASDAQ:ALNY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNa0NRRVBNRzF2MVR0dHFTOGp3RzBVYnNXT1lTRjN3eTlqVDdlVE82bS1vR3BGcjVpRVZESlRObFFsZm1GamhLa3E4TC1zc0llSXhGbHhuU3dzaU04ZDJnSHVqdkpweXFZcno0UFVyOFZSZjRid1RjVENMWG43Z0NWdHliNl83NVJlczFrSEU1LW0zSEdwREJqUTNDYVAwUWdmNmZNdTNnVURyU3JXY3BpSjY3X05HWEVQaWpuU2dncnZYaW1TYU9vMzFxR005UVlXcU1fR0VCcWkxTUdnUWtwdlc5Wks1Vnc1c2dqTGpYRmFmdW84Mmc?oc=5","date":"2025-12-22","type":"pipeline","source":"TechStock²","summary":"Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open - TechStock²","headline":"Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNVDBYa1N5WXIzZDVENDBMY0pLd0VKLTFtcHdXMzRXMVJjYlZucWJ5amRTVGtUX3dpamdWY1dqTUYtenBJek95c2tuQzFSQW5FNmJlM29Kd2JqY3gzY0JrUEExQXF0Y1VTM0dmU2tvbXFTX1k5N1BDLWlLMVVJeDk4dDhPRTFMcjFUOEpDQ0hiOE0zaG1Mc2ZnVDZwOUNYd2twa1pTdXkxdUZZcUNKVk1qRGpibWJibTdWN2tOa2hKX3lwdjBaRkI0Q3ZBbmhFdC13QzdoSWFUOUo4RG9tQ0xlcnZ3?oc=5","date":"2025-12-22","type":"pipeline","source":"TechStock²","summary":"Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook - TechStock²","headline":"Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and th","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNRDBoSG45S3JNT1VZQTRwVHdUc09YdXJ5ZDQ0WjdhMHBkd0pSenZfaWxUQjFWZXR2V1NMdGFFaUN0QzlyUmtUdVVwLXZZdTJYWS1lanI0Y2Y5LUZCUG9UOFExYVV2TGpreGF2OS1IM3lvM0NzcGtCdjlRY25jNS1vS0tTbmk0TXYzVTMtbUdIUktfSnplXzBNMmFKd0ZNaWVuRFhyVm14QU03cEtWbWZrekZ0WkNiM2tyQ1Rj?oc=5","date":"2025-10-31","type":"earnings","source":"Seeking Alpha","summary":"Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak (ALNY) - Seeking Alpha","headline":"Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak (ALNY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNdHE1NWJUbWRxNUJTdGNnM2xrNEs4Xy1qVVJBcGU0eXk3bXdOZHNlX1RiSDBkT0dHa1d1MkcyYjZKZk1rcVU0c3F6RXE2b21Pa0hZNjZTS1lEc2M1dkMyY1Bua3lNUm5WNTktTU5UNDB3THN1YnpQcGNuNFBFN3lOeE9wQ0owenBwX09yd2Jma3BsTFU?oc=5","date":"2025-09-12","type":"pipeline","source":"Seeking Alpha","summary":"Pfizer, Alnylam earn BridgeBio ire over sales tactics for amyloidosis drugs: Bloomberg - Seeking Alpha","headline":"Pfizer, Alnylam earn BridgeBio ire over sales tactics for amyloidosis drugs: Bloomberg","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOZUUtMnN0UkFkVjIxOEJzSnFzWXROdXdFNFNjcTQ0ZV9pNmNkdnhXeWsyOXZjZGFKRWtrMDdhWDBIWEtvcGR2RFUzamtTbjl0WC1YNkxsUE5oTVpCSjFDRS1jNGlpblRFSUg5VWc5TEJ4UGdJWlk1Q2E0eHN1WjhhYV9yUVQ0MktJU3c?oc=5","date":"2025-09-08","type":"deal","source":"Yahoo Finance","summary":"Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth? - Yahoo Finance","headline":"Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-01","type":"pipeline","source":"simplywall.st","summary":"Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - simplywall.st","headline":"Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxNLTE2dUFqNXdFVHU2VExEbENCLVhzQWZpYXFOVVBRMVo5RS1PRjNSV2E5WHFMT19nRGEzZHpOQ295c1ZEUng0STc0ZHlrRG0zOWRvVEtuZ29lT0c0YWo4STQzNERQNUI5UTVqTE1DT01XNXZ6R0swMDRKM0NHME9YNHp3WG5qVkFHY3d4YnQ2akJiR055TkJOZ3ZzTURhZkR3emt1TkFMWVZqTVY5RHNqM1BCQm5LS2RhSWNHVjQ4SzR2cmJWdzNnb2lnS0NUVko1MGVEY3cwLUdPV2k0WWtpOXhDT2hFZVdKZlY1YlVXSmdWRGtDN2FkenU5bmpUaVotYmxHM3NRb2R2NjdWb1h5RkxMM09jZ3BhZlBPd3hUSkQ3MWdSX2hYWUtWZXlxMzBWdjRWYU1jd3NGdVBEczdyTjVkNlh4VmQ3b2J5M3cwZzBQYVcxSEE?oc=5","date":"2024-04-30","type":"deal","source":"BioSpace","summary":"Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including","headline":"Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel t","sentiment":"neutral"}],"patents":[{"drugName":"Onpattro","drugSlug":"patisiran","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Givlaari","drugSlug":"givosiran","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":1100000000},{"drugName":"Oxlumo","drugSlug":"lumasiran","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":500000000}],"drugCount":5,"phaseCounts":{"marketed":5},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Ionis Pharmaceuticals","Sarepta Therapeutics"],"therapeuticFocus":["Rare genetic diseases","RNA interference (RNAi) therapeutics"],"financials":{"source":"sec_edgar","revenue":1037418000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":1037418000,"period":"2022-12-31"},{"value":844287000,"period":"2021-12-31"},{"value":844287000,"period":"2021-12-31"},{"value":492853000,"period":"2020-12-31"},{"value":492853000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":1319775000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":313747000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":4966331000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":327.49,"previousClose":319.52,"fiftyTwoWeekHigh":495.55,"fiftyTwoWeekLow":205.87,"fiftyTwoWeekRange":"205.87 - 495.55","fiftyDayAverage":327.88,"twoHundredDayAverage":393.35,"beta":0.38,"enterpriseValue":42436059136,"forwardPE":23.1,"priceToBook":54.93,"priceToSales":11.69,"enterpriseToRevenue":11.43,"enterpriseToEbitda":76.16,"pegRatio":0.64,"ebitda":557235968,"ebitdaMargin":15,"freeCashflow":128788376,"operatingCashflow":524080000,"totalDebt":2968797952,"debtToEquity":376.2,"currentRatio":2.76,"returnOnAssets":6.8,"returnOnEquity":73.3,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":25,"targetMeanPrice":449.32,"targetHighPrice":566,"targetLowPrice":310,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.5,"institutionHeldPercent":101.7,"sharesOutstanding":132623144,"floatShares":132080715,"sharesShort":4369615,"shortRatio":4.2,"shortPercentOfFloat":3.3,"epsTrailing":2.33,"epsForward":14.2,"revenuePerShare":28.35,"bookValue":5.96,"officers":[{"age":62,"name":"Dr. Yvonne L. Greenstreet M.B.A., M.D.","title":"CEO & Director"},{"age":80,"name":"Dr. Phillip A. Sharp Ph.D.","title":"Co-Founder, Member of the Scientific Advisory Board"},{"age":57,"name":"Mr. Jeffrey V. Poulton M.B.A.","title":"CFO & Executive VP"},{"age":56,"name":"Dr. Kevin Joseph Fitzgerald Ph.D.","title":"Executive VP, Chief Scientific Officer and Head of Early Research & Early Development"},{"age":57,"name":"Dr. Pushkal P. Garg M.D.","title":"Chief Research & Development Officer"},{"age":51,"name":"Mr. Tolga  Tanguler M.B.A.","title":"Executive VP & Chief Commercial Officer"},{"age":null,"name":"Mr. Timothy J. Maines","title":"Chief Technical Operations & Quality Officer"},{"age":null,"name":"Mr. Piyush  Sharma J.D.","title":"Chief Ethics & Compliance Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.alnylam.com","phone":"617 551 8200"}}